Cappelaere P, Chauvergne J, Klein T, Gary-Bobo J, Guerrin J, Meeus L
Bull Cancer. 1981;68(5):422-7.
In a randomized multicenter trial, 151 patients, with advanced epidermoid carcinoma of the head, neck and oesophagus, were treated with an association of vincristin, methotrexate, bleomycin and cis-platin (group I) or detorubicin (group II). Prognostic factors were equally distributed for the both groups. Partial or complete responses were obtained in 22 patients of group I (29 p. cent) and 9 in group II (12 p. cent, p less than 0.05). Objective response rates were higher in untreated patients or those in good condition but the difference was not statistically significant. Five probably treatment induced deaths (3 p. cent) were observed. Treatment was stopped in 2 patients (15 p. cent) for haematological, general or digestive toxicity. This trial confirms the efficacy of vincristin, methotrexate, bleomycin and cis-platin for advanced head and neck carcinomas.
在一项随机多中心试验中，151例头颈部及食管晚期表皮样癌患者接受了长春新碱、甲氨蝶呤、博来霉素和顺铂联合治疗（第一组）或多柔比星治疗（第二组）。两组的预后因素分布均衡。第一组22例患者（29%）获得部分或完全缓解，第二组9例患者（12%，P<0.05）获得部分或完全缓解。未治疗患者或身体状况良好患者的客观缓解率更高，但差异无统计学意义。观察到5例可能由治疗引起的死亡（3%）。2例患者（15%）因血液学、全身或消化系统毒性而停止治疗。该试验证实了长春新碱、甲氨蝶呤、博来霉素和顺铂治疗晚期头颈部癌的疗效。
